Multidrug and Extensively Drug-resistant Tuberculosis in Canada 1997-2008: Demographic and Disease Characteristics

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Minion, Jessica ^a   Gallant, Victor ^b   Wolfe, Joyce ^c   Jamieson, Frances ^d   Long, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CANADA; CHILD; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CANADA; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84872250825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053466     Document Type: Article

References (20)

1. Public Health Agency of Canada & Canadian Lung Association/Canadian Thoracic Society (2007) Canadian Tuberculosis Standards, Sixth Edition (eds. R. Long R and E. Ellis), Her Majesty the Queen in Right of Canada, represented by the Minister of Health Ottawa, Canada. Available: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/pdf/tbstand07_e.pdf. Accessed 2012 Oct 18.
2. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, et al. (2010) MDR tuberculosis-critical steps for prevention and control. N Engl J Med 363: 1050-1058. Epub 2010/09/10.
3. World Health Organization. (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Available: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed: 2012 Oct 18.
4. Clinical and Laboratory Standards Institute (CLSI). (2003) Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; Approved standard, M24-A.: Clinical and Laboratory Standards Institute.
5. World Health Organization. (2006) The Global Plan to Stop TB 2006-2015: Annex 1, Methods used to estimate costs, funding and funding gaps. Available: http://whqlibdoc.who.int/publications/2006/924159487X_eng.pdf. Accessed 2012 Dec 2.
6. World Health Organization, Stop TB Department. (2008) Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Available: http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf. Accessed 2012 Sept 29.
7. Hah NS, Wright A, Drobniewski F, Rusch-Gerdes S, Havelkova M, et al. (2005) Extreme drug resistance in tuberculosis ("XDR-TB"): global survey of supernational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis 9: S77.
8. Centers for Disease Control and Prevention (CDC) (2006) Emergence of Mycobaterium tuberculosis with extensive resistance to second-line drugs- world wide, 2000-2004. Morb Mortal Wkly Rep 55: 301-305.
9. Fay MP (2010) Confidence intervals that match Fisher's exact or Blaker's exact tests. Biostatistics 11: 373-374. Epub 2009/12/02.
10. Long R, Nobert E, Chomyc S, van Embden J, McNamee C, et al. (1999) Transcontinental spread of multidrug-resistant Mycobacterium bovis. Am J Respir Crit Care Med 159: 2014-2017. Epub 1999/06/03.
11. Pai M, Minion J, Steingart K, Ramsay A (2010) New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16: 271-284. Epub 2010/03/13.
12. Avendano M, Goldstein RS (2000) Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 7: 383-389. Epub 2000/11/01.
13. Hersi A, Elwood K, Cowie R, Kunimoto D, Long R, (1999) Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998. Can Respir J 6: 155-160.
14. Marras TK, Wilson J, Wang EE, Avendano M, Yang JW, (2003) Tuberculosis among Tibetan refugee claimants in Toronto: 1998 to 2000. Chest 124: 915-921.
15. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, et al. (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38: 516-528. Epub 2011/08/11.
16. Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili JC, et al. (2012) Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 380; 1406-1417.
17. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T (2012) Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Org 90; 693-698. Epub 2012/05/29.
18. Sharma M, Thibert L, Chedore P, Shandro C, Jamieson F, et al. (2011) Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 49: 4112-4116.
19. Seoudi N, Mitchell SL, Brown TJ, Dashti F, Amin AK, et al. (2012) Rapid Molecular detection of tuberculosis and rifampicin drug resistance: retrospective analysis of a national UK molecular service over the last decade. Thorax 67: 361-367. Epub 2012 Jan 2.
20. Long R, Langlois-Klassen D (2012) Increase in multi-drug resistant tuberculosis (MDR-TB) in Alberta among foreign-born persons: implications for tuberculosis management. Can J Public Health; In press.